Today's TGTX Run/Thoughts/Prediction
Yes Doug, I think we are definitely in a relative value realization/digestion mode.
But, even with the seemingly large run we've seen the last few days, what should both sustain it and drive it(perhaps much) further, is recognition of the fact that, at the current market cap of approx. 430 ml,
the company is still relatively very cheap...
all one needs to do is look at the recent INFI/ABBV duvelisib deal, with upfront & milestones over 800ml, plus hefty additional royalties, for a single drug which has real tox (& therefore combo)questions,
and it becomes obvious that TGTX, with a comparable drug(TGR-1202, with the advantages of no tox to date(approx. 2 yrs data), high efficacy, and once vs twice a day dosing), not to mention another likely BIC anti CD20(TG-1101,in combo with Ibrutinib prog, plus inhouse with TGR-1202), plus a new IRAK4 program...
and, I repeat, it becomes obvious that TGTX is still extremely undervalued, period!
Best regards,
bw
